Schedule 13G ownership disclosure

VYNE Therapeutics Inc.

Security class unavailable

Event date: 2023-11-01

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
890,868
Percent of class
6.4000%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001213900-23-082782
Form type
SC 13G
Filer
Soleus Capital Master Fund, L.P.
CIK
CIK 1812275
Filed
Nov 02, 2023
Reporting period
Nov 01, 2023
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub